enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
公司代码NVNO
公司名称enVVeno Medical Corp
上市日期May 31, 2018
CEOBerman (Robert A)
员工数量37
证券类型Ordinary Share
年结日May 31
公司地址70 Doppler
城市IRVINE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编92618
电话19492612900
网址https://envveno.com/
公司代码NVNO
上市日期May 31, 2018
CEOBerman (Robert A)